Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VM0 | ISIN: US8902608392 | Ticker-Symbol: TPM0
Tradegate
06.06.25 | 15:45
34,000 Euro
+1,19 % +0,400
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TONIX PHARMACEUTICALS HOLDING CORP Chart 1 Jahr
5-Tage-Chart
TONIX PHARMACEUTICALS HOLDING CORP 5-Tage-Chart
RealtimeGeldBriefZeit
33,80034,40015:52

Aktuelle News zur TONIX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.05.Tonix Pharmaceuticals Holding Corp. - S-8, Securities to be offered to employees in employee benefit plans7
22.05.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase27
21.05.Tonix begins trial for stress reaction treatment5
21.05.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report1
TONIX PHARMACEUTICALS Aktie jetzt für 0€ handeln
21.05.Tonix beginnt Studie zur Behandlung von Stressreaktionen7
21.05.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction160Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University...
► Artikel lesen
16.05.Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results22
12.05.Tonix Pharmaceuticals GAAP EPS of -$2.84 beats by $0.39, revenue of $2.43M misses by $0.12M6
12.05.Tonix Pharmaceuticals Holding Corp. - 10-Q, Quarterly Report3
12.05.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights2.135FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced...
► Artikel lesen
08.05.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report4
29.04.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting13
28.04.Tonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woes12
24.04.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 202510
24.04.Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report9
16.04.Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 20256
10.04.Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday?7
09.04.Tonix und Makana kooperieren bei Xenotransplantationsforschung5
09.04.Tonix and Makana partner on xenotransplantation research1
09.04.Tonix, Makana Enter Preclinical Research And Development Collaboration2
Weiter >>
103 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2